JP2018524339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524339A5 JP2018524339A5 JP2017567655A JP2017567655A JP2018524339A5 JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5 JP 2017567655 A JP2017567655 A JP 2017567655A JP 2017567655 A JP2017567655 A JP 2017567655A JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- alkyl
- compound
- optionally
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 125000001424 substituent group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 201000008827 tuberculosis Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 150000001408 amides Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000003262 carboxylic acid ester group Chemical class [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000002346 iodo group Chemical group I* 0.000 claims description 2
- 125000004957 naphthylene group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- -1 when X b is N Chemical compound 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 C*(CC(C)(C1)**1I)*IN* Chemical compound C*(CC(C)(C1)**1I)*IN* 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021194493A JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15174936.3 | 2015-07-02 | ||
| EP15174936 | 2015-07-02 | ||
| EP16174718.3 | 2016-06-16 | ||
| EP16174713 | 2016-06-16 | ||
| EP16174718 | 2016-06-16 | ||
| EP16174713.4 | 2016-06-16 | ||
| PCT/EP2016/065499 WO2017001660A1 (en) | 2015-07-02 | 2016-07-01 | Antibacterial compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194493A Division JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524339A JP2018524339A (ja) | 2018-08-30 |
| JP2018524339A5 true JP2018524339A5 (enExample) | 2019-08-08 |
| JP7099824B2 JP7099824B2 (ja) | 2022-07-12 |
Family
ID=56289523
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567289A Pending JP2018519302A (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2017567655A Active JP7099824B2 (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
| JP2021194493A Active JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567289A Pending JP2018519302A (ja) | 2015-07-02 | 2016-07-01 | 抗菌化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194493A Active JP7516338B2 (ja) | 2015-07-02 | 2021-11-30 | 抗菌化合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US10364232B2 (enExample) |
| EP (3) | EP4074378A1 (enExample) |
| JP (3) | JP2018519302A (enExample) |
| KR (2) | KR102710552B1 (enExample) |
| CN (3) | CN108235704B (enExample) |
| AU (3) | AU2016287477B2 (enExample) |
| BR (1) | BR112017028318B1 (enExample) |
| CA (1) | CA2986331A1 (enExample) |
| CL (1) | CL2017003404A1 (enExample) |
| CO (1) | CO2017013408A2 (enExample) |
| DK (1) | DK3316969T3 (enExample) |
| EA (2) | EA201890201A1 (enExample) |
| ES (1) | ES2914681T3 (enExample) |
| HK (1) | HK1249468A1 (enExample) |
| HR (1) | HRP20220339T1 (enExample) |
| IL (2) | IL256391B (enExample) |
| LT (1) | LT3316969T (enExample) |
| MA (1) | MA42293A (enExample) |
| MD (1) | MD3316969T2 (enExample) |
| MX (2) | MX386598B (enExample) |
| PE (1) | PE20180520A1 (enExample) |
| PH (2) | PH12017502298A1 (enExample) |
| PL (1) | PL3316969T3 (enExample) |
| RS (1) | RS63201B1 (enExample) |
| SI (1) | SI3316969T1 (enExample) |
| SM (1) | SMT202200220T1 (enExample) |
| UA (1) | UA125171C2 (enExample) |
| WO (2) | WO2017001661A1 (enExample) |
| ZA (1) | ZA201708692B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017003658B1 (pt) | 2014-08-28 | 2022-12-06 | Asceneuron Sa | Composto, mistura, método para inibição de uma glicosidase, e, composição farmacêutica |
| TWI788830B (zh) | 2015-07-02 | 2023-01-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| EP4074378A1 (en) | 2015-07-02 | 2022-10-19 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| US10919888B2 (en) | 2015-09-17 | 2021-02-16 | University Of Notre Dame Du Lac | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
| EP3585783A2 (en) | 2016-02-25 | 2020-01-01 | Asceneuron SA | Sulfoximine glycosidase inhibitors |
| EP3419976B1 (en) | 2016-02-25 | 2021-04-07 | Asceneuron SA | Acid addition salts of piperazine derivatives |
| US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| EA201990043A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Антибактериальные соединения |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CN110267961A (zh) * | 2017-02-06 | 2019-09-20 | 詹森药业有限公司 | Oga抑制剂化合物 |
| EP4417262A3 (en) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Combination therapy |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| EP3697781B1 (en) | 2017-10-17 | 2023-06-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| ES3064093T3 (en) | 2017-10-20 | 2026-04-22 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| RU2680972C1 (ru) * | 2018-02-13 | 2019-03-01 | Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" | Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков |
| US20210009583A1 (en) * | 2018-03-12 | 2021-01-14 | University Of Notre Dame Du Lac | Deuterated imidazopyridines |
| JP7398391B2 (ja) | 2018-04-20 | 2023-12-14 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| EP3841093B1 (en) | 2018-08-22 | 2023-06-21 | Asceneuron SA | Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| CN109503631A (zh) * | 2018-12-29 | 2019-03-22 | 中国医学科学院医药生物技术研究所 | 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用 |
| EP3976031A4 (en) * | 2019-05-28 | 2023-07-12 | Shionogi & Co., Ltd | MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A MYCOBACTERIAL INFECTION CHARACTERIZED BY THE COMBINATION OF A BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE |
| KR102076958B1 (ko) | 2019-06-24 | 2020-02-13 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
| TWI861208B (zh) | 2019-09-10 | 2024-11-11 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物 |
| KR102955654B1 (ko) | 2019-09-13 | 2026-04-21 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균 화합물 |
| KR20220071199A (ko) | 2019-09-30 | 2022-05-31 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4-퀴놀리논 항균 화합물 |
| MX2022003816A (es) | 2019-09-30 | 2022-05-06 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos. |
| CN114867528B (zh) | 2019-12-27 | 2024-03-19 | 社会医疗技术员技术股份公司 | 抗菌喹啉类 |
| KR20230157400A (ko) | 2021-03-16 | 2023-11-16 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항박테리아성 화합물 |
| WO2022194905A1 (en) | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3212074A1 (en) | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214519A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022214520A1 (en) | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| KR20240000574A (ko) * | 2021-04-23 | 2024-01-02 | 에프. 호프만-라 로슈 아게 | 헤테로시클릭 화합물 |
| CA3223626A1 (en) | 2021-06-29 | 2023-01-05 | Augusto Eugenio Pardal Filipe | Heterocyclic compounds for the treatment of tuberculosis |
| TW202325274A (zh) | 2021-10-28 | 2023-07-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 抗菌化合物 |
| US20250154145A1 (en) * | 2021-12-20 | 2025-05-15 | Fairhaven Pharmaceuticals Ins. | Oxer1 antagonists and uses thereof |
| CN114957954B (zh) * | 2022-05-16 | 2024-08-20 | 万华化学集团股份有限公司 | 一种用于光学透镜的热塑性树脂组合物及其制备方法和应用 |
| IL316870A (en) * | 2022-06-15 | 2025-01-01 | C4 Therapeutics Inc | Compounds for targeted unloading of SMARCA2 |
| TW202409040A (zh) | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025017047A1 (en) | 2023-07-18 | 2025-01-23 | Janssen Pharmaceutica Nv | Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections |
| WO2025129116A1 (en) * | 2023-12-14 | 2025-06-19 | C4 Therapeutics, Inc. | Compounds for the targeted degradation of smarca2 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9509673A (pt) | 1994-11-15 | 1997-09-30 | Upjohn Co | Compostos e uso dos mesmos |
| AU702752B2 (en) | 1995-05-11 | 1999-03-04 | Pharmacia & Upjohn Company | Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones |
| PT1527050E (pt) | 2002-07-25 | 2010-06-22 | Janssen Pharmaceutica Nv | Derivados de quinolina e sua utilização como inibidores de micobactérias |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| WO2008082490A2 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| CL2008001631A1 (es) * | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| CN101965353B (zh) | 2008-03-26 | 2014-12-17 | 丹诺医药(苏州）有限公司 | 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类 |
| EP2353008A2 (en) | 2008-09-22 | 2011-08-10 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| EP2379513A1 (en) | 2008-12-30 | 2011-10-26 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
| CN110483499A (zh) | 2009-11-05 | 2019-11-22 | 圣母大学 | 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法 |
| ES2572387T3 (es) * | 2010-03-18 | 2016-05-31 | Pasteur Institut Korea | Compuestos anti-infecciosos |
| WO2012143796A2 (en) | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| US20150011508A1 (en) | 2011-09-01 | 2015-01-08 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| WO2013033167A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| DK2820008T3 (en) | 2012-03-02 | 2017-03-27 | Genentech Inc | AMIDO-SPIROCYCLIC AMIDE AND SULPHONAMIDE DERIVATIVES |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| CA2879460C (en) | 2012-07-18 | 2021-10-19 | Garrett MORASKI | 5,5-heteroaromatic anti-infective compounds |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| US20160185774A1 (en) * | 2013-08-02 | 2016-06-30 | Institut Pasteur Korea | Anti-Infective Compounds |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| JP2017533220A (ja) | 2014-11-03 | 2017-11-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 結核処置のための多剤療法 |
| EP4074378A1 (en) | 2015-07-02 | 2022-10-19 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| EA201990043A1 (ru) | 2016-06-16 | 2019-05-31 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Антибактериальные соединения |
| KR20190018681A (ko) | 2016-06-16 | 2019-02-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균제로서의 헤테로고리 화합물 |
| EP4417262A3 (en) | 2017-03-01 | 2024-11-27 | Janssen Sciences Ireland Unlimited Company | Combination therapy |
-
2016
- 2016-07-01 EP EP22158386.7A patent/EP4074378A1/en not_active Withdrawn
- 2016-07-01 CA CA2986331A patent/CA2986331A1/en not_active Abandoned
- 2016-07-01 PL PL16734637T patent/PL3316969T3/pl unknown
- 2016-07-01 AU AU2016287477A patent/AU2016287477B2/en active Active
- 2016-07-01 HK HK18109081.1A patent/HK1249468A1/zh unknown
- 2016-07-01 WO PCT/EP2016/065503 patent/WO2017001661A1/en not_active Ceased
- 2016-07-01 HR HRP20220339TT patent/HRP20220339T1/hr unknown
- 2016-07-01 DK DK16734637.8T patent/DK3316969T3/da active
- 2016-07-01 UA UAA201800904A patent/UA125171C2/uk unknown
- 2016-07-01 BR BR112017028318-2A patent/BR112017028318B1/pt active IP Right Grant
- 2016-07-01 PE PE2017002738A patent/PE20180520A1/es unknown
- 2016-07-01 AU AU2016287478A patent/AU2016287478B2/en not_active Expired - Fee Related
- 2016-07-01 LT LTEPPCT/EP2016/065499T patent/LT3316969T/lt unknown
- 2016-07-01 MX MX2017016788A patent/MX386598B/es unknown
- 2016-07-01 EP EP16734637.8A patent/EP3316969B1/en active Active
- 2016-07-01 EP EP16733105.7A patent/EP3316968A1/en not_active Ceased
- 2016-07-01 CN CN201680038644.7A patent/CN108235704B/zh active Active
- 2016-07-01 MD MDE20180478T patent/MD3316969T2/ro not_active IP Right Cessation
- 2016-07-01 SM SM20220220T patent/SMT202200220T1/it unknown
- 2016-07-01 MX MX2017016789A patent/MX2017016789A/es unknown
- 2016-07-01 US US15/736,375 patent/US10364232B2/en active Active
- 2016-07-01 CN CN202111173668.2A patent/CN113980015A/zh active Pending
- 2016-07-01 MA MA042293A patent/MA42293A/fr unknown
- 2016-07-01 JP JP2017567289A patent/JP2018519302A/ja active Pending
- 2016-07-01 EA EA201890201A patent/EA201890201A1/ru unknown
- 2016-07-01 RS RS20220464A patent/RS63201B1/sr unknown
- 2016-07-01 ES ES16734637T patent/ES2914681T3/es active Active
- 2016-07-01 US US15/736,524 patent/US20180155341A1/en not_active Abandoned
- 2016-07-01 KR KR1020187001923A patent/KR102710552B1/ko active Active
- 2016-07-01 EA EA201890204A patent/EA201890204A1/ru unknown
- 2016-07-01 KR KR1020187002072A patent/KR20180022833A/ko not_active Ceased
- 2016-07-01 WO PCT/EP2016/065499 patent/WO2017001660A1/en not_active Ceased
- 2016-07-01 JP JP2017567655A patent/JP7099824B2/ja active Active
- 2016-07-01 CN CN201680038659.3A patent/CN107708809A/zh active Pending
- 2016-07-01 SI SI201631501T patent/SI3316969T1/sl unknown
-
2017
- 2017-12-13 PH PH12017502298A patent/PH12017502298A1/en unknown
- 2017-12-13 PH PH12017502297A patent/PH12017502297A1/en unknown
- 2017-12-18 IL IL256391A patent/IL256391B/en active IP Right Grant
- 2017-12-18 IL IL256379A patent/IL256379A/en unknown
- 2017-12-20 ZA ZA2017/08692A patent/ZA201708692B/en unknown
- 2017-12-26 CO CONC2017/0013408A patent/CO2017013408A2/es unknown
- 2017-12-27 CL CL2017003404A patent/CL2017003404A1/es unknown
-
2019
- 2019-07-02 US US16/460,334 patent/US20190330189A1/en not_active Abandoned
-
2020
- 2020-04-14 US US16/848,337 patent/US11180472B2/en active Active
-
2021
- 2021-09-17 US US17/477,970 patent/US11866419B2/en active Active
- 2021-11-30 JP JP2021194493A patent/JP7516338B2/ja active Active
-
2022
- 2022-01-20 AU AU2022200385A patent/AU2022200385B2/en active Active
-
2023
- 2023-11-29 US US18/523,171 patent/US20240132470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519302A5 (enExample) | ||
| JP2019518046A5 (enExample) | ||
| JP2019518050A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2008195730A5 (enExample) | ||
| JP2020510015A5 (enExample) | ||
| JP2022500425A5 (enExample) | ||
| JP2020510010A5 (enExample) | ||
| JP2006507265A5 (enExample) | ||
| KR940005566A (ko) | 퀴놀린 화합물 | |
| JP2014500295A5 (enExample) | ||
| JP2023544476A5 (enExample) | ||
| JP2004517099A5 (enExample) | ||
| JP2008201787A5 (enExample) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2013542267A5 (enExample) | ||
| JP2019519616A5 (enExample) | ||
| JP2014505017A5 (enExample) | ||
| JP2021525787A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2024539645A (ja) | インテグリン阻害剤及び他の薬剤と組み合わせたその使用 | |
| JP2024507414A5 (enExample) | ||
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| JP2015522592A5 (enExample) | ||
| JP2024517769A5 (enExample) |